From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer - Takeaways - MDSpire

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

  • By

  • Ming Jin

  • Zhenzhen Cai

  • Ming Bu

  • Jicheng Liu

  • Xiaojie Zhang

  • May 29, 2026

  • 0 min

Share

  • 1

    Bladder cancer is a common malignancy, with gemcitabine playing a central role in various treatment regimens for different stages.

  • 2

    Gemcitabine resistance can occur due to primary non-response or acquired resistance, often recognized only after clinical deterioration.

  • 3

    A 3-stage model of gemcitabine resistance includes early pharmacologic resistance, intermediate resistance, and late adaptive resistance.

  • 4

    Mechanistic nodes of resistance are stratified by clinical evidence quality, with most findings remaining at the preclinical stage.

  • 5

    Future research should focus on translating mechanistic discoveries into clinically actionable tools and strategies for bladder cancer.

Original Source(s)

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

  • by Ming Jin, Zhenzhen Cai, Ming Bu, Jicheng Liu, Xiaojie Zhang

  • May 29, 2026

Related Content

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review